395 related articles for article (PubMed ID: 29653212)
1. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
[TBL] [Abstract][Full Text] [Related]
2. The association of BRAF V600E gene mutation with proliferative activity and histopathological characteristics of congenital melanocytic nevi in children.
Chen J; Zhang G; Liu X; Tu P
An Bras Dermatol; 2023; 98(4):498-505. PubMed ID: 37156689
[TBL] [Abstract][Full Text] [Related]
3. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
[TBL] [Abstract][Full Text] [Related]
4. Melanocytic nevi and melanoma: unraveling a complex relationship.
Damsky WE; Bosenberg M
Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
[TBL] [Abstract][Full Text] [Related]
5. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
Yeh I; von Deimling A; Bastian BC
J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527
[TBL] [Abstract][Full Text] [Related]
6. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
9. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
10. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
[TBL] [Abstract][Full Text] [Related]
11. Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population.
Wu D; Wang M; Wang X; Yin N; Song T; Li H; Yu J; Wang DM; Zhao Z
Am J Dermatopathol; 2011 Jun; 33(4):341-4. PubMed ID: 21430505
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary melanocytic nevus - A case report with a mutation analysis of common driver oncogenes.
Tanaka M; Matsumura M; Okudela K; Mitsui H; Tateishi Y; Umeda S; Suzuki T; Koike C; Kataoka T; Kawano N; Kojima Y; Osawa H; Ohashi K
Pathol Int; 2019 Nov; 69(11):667-671. PubMed ID: 31556191
[TBL] [Abstract][Full Text] [Related]
13. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
14. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
16. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
Wu J; Rosenbaum E; Begum S; Westra WH
Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
[TBL] [Abstract][Full Text] [Related]
17. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
[TBL] [Abstract][Full Text] [Related]
18. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
19. BRAF
McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
Elife; 2021 Nov; 10():. PubMed ID: 34812139
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]